Please assess the completion status of the following clinical trial:

Trial Title: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of schizophrenia or schizoaffective disorder and a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening.~* Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.~* Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.~* Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study.~* Female subjects must not be pregnant.~* Be in good general health and expected to complete the clinical study as designed.~* Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).~* Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.~* Have a negative alcohol breath test at screening and study start.~Exclusion Criteria:~* Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening.~* Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).~* Have a known history of neuroleptic malignant syndrome.~* Have a significant risk of suicidal or violent behavior.~* Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine.~* Receiving medication for the treatment of tardive dyskinesia.~* Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a history of positive result.~* Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.~* Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~* Have had previous exposure with NBI-98854.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NBI-98854 50 mg (Type: EXPERIMENTAL): NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
- NBI-98854 100 mg and 50 mg (Type: EXPERIMENTAL): NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete